Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 known ✓ | P49768 | 8/20 | 0.49 |
| ▸ | PSEN2 known ✓ | P49810 | 8/20 | 0.49 |
| ▸ | APH1B known ✓ | Q8WW43 | 8/20 | 0.49 |
| ▸ | NCSTN known ✓ | Q92542 | 8/20 | 0.49 |
| ▸ | APH1A known ✓ | Q96BI3 | 8/20 | 0.49 |
| ▸ | PSENEN known ✓ | Q9NZ42 | 8/20 | 0.49 |
| ▸ | GABRP | O00591 | 1/20 | 0.73 |
| ▸ | GABRD | O14764 | 1/20 | 0.73 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.73 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.73 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.73 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.73 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.73 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.73 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.73 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.73 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.73 |
| ▸ | GABRE | P78334 | 1/20 | 0.73 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.73 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6797581 | 1.00 | GABRP (0.73) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4115829 | 0.99 | GABRP (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3287888 | 0.99 | GABRP (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3289463 | 0.99 | GABRP (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL6797572 | 0.96 | GABRP (0.71) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL3486697 | 0.87 | GABRP (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3487036 | 0.86 | GABRP (0.70) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3287133 | 0.85 | GABRP (0.80) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2923672 | 0.85 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1835654 | 0.85 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713476-B2 | SUBSTITUTED LACTAM; GAMMA-SECRETASE INHIBITOR; DECREASES PRODUCTION OF BETA-AMYLOID; TREATMENT FOR ALTZHEIMER'S AND DOWN'S SYNDROME | DUPONT PHARMACEUTICALS COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | APP, BACE1, APH1A | PSEN1 6/4885PSEN2 8/4885APH1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.